.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,006,175

« Back to Dashboard

Details for Patent: 9,006,175

Title:Potentiation of glucose elimination
Abstract: Methods related to the treatment of diabetes and improving the efficiency of insulin utilization are provided. The method enables effective control of prandial glucose levels while reducing the risk of postprandial hypoglycemia. In particular, methods of potentiating the activity of endogenous insulin in type 2 diabetics and exogenous long-acting insulin in diabetics requiring basal insulin replacement are provided.
Inventor(s): Boss; Anders Hasager (Princeton, NJ), Steiner; Solomon S. (Mount Kisco, NY), Woods; Rodney J. (New Hampton, NY), Sulner; Joseph W. (Paramus, NJ)
Assignee: MannKind Corporation (Valencia, CA)
Filing Date:Jan 10, 2006
Application Number:11/329,686
Claims:1. A method of potentiating the glucose elimination rate in a human patient with diabetes comprising: producing a spike in serum insulin concentration with an exogenously-administered inhaled insulin composition, wherein said spike comprises the maximum serum insulin concentration which is obtained by about 20 minutes after administration of said inhaled insulin composition, and wherein said exogenously-administered inhaled insulin composition is administered from approximately 10 minutes prior to a meal to approximately 30 minutes after a meal, wherein said glucose elimination rate returns to baseline by about 6 hours after administration.

2. The method of claim 1 wherein said diabetes is type 2 diabetes.

3. The method of claim 1 wherein said maximum serum insulin concentration is about 75 mU/L or greater than 75 mU/L.

4. The method of claim 3 wherein said maximum serum insulin concentration is about 100 mU/L or greater than 100 mU/L.

5. The method of claim 4 wherein said maximum serum insulin concentration is about 125 mU/L or greater than 125 mU/L.

6. The method of claim 1 wherein said maximum serum insulin concentration is achieved within about 15 minutes.

7. The method of claim 6 wherein said maximum serum insulin concentration is achieved within about 10 minutes.

8. The method of claim 1 wherein said potentiation comprises the glucose elimination rate reaching its maximum within about 30 to 90 minutes after administration of said inhaled insulin composition.

9. The method of claim 8 wherein said potentiation comprises the glucose elimination rate reaching its maximum within about 1 hour.

10. The method of claim 9 wherein said potentiation comprises the glucose elimination rate reaching its maximum within about 45 minutes.

11. The method of claim 1 wherein said serum insulin concentration descends through half-maximal by about 80 minutes after said maximum serum insulin concentration is achieved.

12. The method of claim 11, wherein said serum insulin concentration descends through half-maximal by about 50 minutes after said maximum serum insulin concentration is achieved.

13. The method of claim 1 wherein said glucose elimination rate continues to rise after serum insulin concentration begins to fall.

14. The method of claim 1 wherein said glucose elimination rate begins to fall by about 1 hour after insulin administration.

15. The method of claim 1 wherein said exogenously-administered inhaled insulin composition comprises a complex between a diketopiperazine and human insulin.

16. The method of claim 15 wherein said diketopiperazine is fumaryl diketopiperazine.

17. A method of treating an insulin-related disorder comprising: administering to a human patient having diabetes an exogenously-administered inhaled insulin composition such that said exogenously-administered inhaled insulin composition produces a spike in serum insulin concentration wherein said spike comprises the maximum serum insulin concentration which is achieved by about 20 minutes after administration of said inhaled insulin composition, and wherein said exogenously-administered inhaled insulin composition is administered from approximately 10 minutes prior to a meal to approximately 30 minutes after a meal, and wherein the glucose elimination rate of the human patient returns to baseline by about 6 hours after administration.

18. The method of claim 17 wherein said exogenously-administered inhaled insulin composition comprises a complex between a diketopiperazine and human insulin.

19. The method of claim 18 wherein said diketopiperazine is fumaryl diketopiperazine.

20. The method of claim 17 wherein said diabetes is type 2 diabetes.

21. The method of claim 17 further comprising administering a long-acting basal insulin.

22. The method of claim 17 wherein said serum insulin concentration descends through half-maximal by about 80 minutes after said maximum serum insulin concentration is achieved.

23. The method of claim 22 wherein said serum insulin concentration descends through half-maximal by about 50 minutes after said maximum serum insulin concentration is achieved.

24. A method of maintaining blood glucose levels in a human patient with diabetes in a normal range comprising: providing an exogenously-administered inhaled insulin composition, such that said exogenously administered inhaled insulin composition produces a spike in serum insulin concentration comprising maximum serum insulin concentration achieved within about 30 minutes of administration of said inhaled insulin composition, and wherein said exogenously-administered inhaled insulin composition is administered from approximately 10 minutes prior to a meal to approximately 30 minutes after a meal, and wherein the glucose elimination rate of the human patient returns to baseline by about 6 hours after administration.

25. The method of claim 24 wherein said maximum serum insulin concentration is obtained within about 15 minutes of administration.

26. The method of claim 25 wherein said exogenously-administered inhaled insulin composition comprises a complex between a diketopiperazine and human insulin.

27. The method of claim 26 wherein said diketopiperazine is fumaryl diketopiperazine.

28. The method of claim 24 wherein said exogenously-administered inhaled insulin composition is a non-naturally occurring form of insulin.

29. The method of claim 24 wherein said serum insulin concentration descends through half-maximal by about 80 minutes after said maximum serum insulin concentration is achieved.

30. The method of claim 29 wherein said serum insulin concentration descends through half-maximal by about 50 minutes after said maximum serum insulin concentration is achieved.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc